A Quantitative Framework to Evaluate Proarrhythmic Risk in a First‐in‐Human Study to Support Waiver of a Thorough QT Study. Issue 6 (29th September 2015)

• Record Type: Journal Article
• Authors: Nelson, CH; Wang, L; Fang, L; Weng, W; Cheng, F; Hepner, M; Lin, J; Garnett, C; Ramanathan, S
• Is Part Of: Clinical pharmacology & therapeutics. Volume 98:Issue 6(2015:Dec.)
• Page Start: 630
• Page End: 638
• Publication Date: 2015-09-29
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.204
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : The effects of GS‐4997 (apoptosis signal‐regulating kinase 1 inhibitor) on cardiac repolarization were evaluated using a systematic modeling approach in a first‐in‐human (FIH) study. High quality, intensive, time‐matched 12‐lead electrocardiograms (ECGs) were obtained in this placebo‐controlled, single and multiple‐ascending dose study in healthy subjects. Model development entailed linearity and hysteresis assessments; GS‐4997/metabolite concentration vs. baseline‐adjusted QTcF (ΔQTcF) relationships were determined using linear mixed effects models. Bootstrapping was used to obtain 90% confidence intervals (CIs) of predicted placebo‐corrected ΔQTcF (ΔΔQTcF). The upper bound of 90% CI for predicted ΔΔQTcF was <10 msec at therapeutic and supratherapeutic GS‐4997/metabolite levels, indicating the absence of a QT prolongation effect. Model performance/suitability was assessed using sensitivity/specificity analyses and diagnostic evaluations. This comprehensive methodology, supported by clinical pharmacology characteristics, was deemed adequate to assess the proarrhythmic risk of GS‐4997/metabolite by the US Food and Drug Administration and European Medicines Agency resulting in a successful waiver from a dedicated thorough QT (TQT) study.